A new randomized, prospective trial has shown that orlistat, a commonly prescribed inhibitor of fat absorption, does not help patients with fatty liver disease lose weight, nor does it improve their liver enzymes or insulin resistance.
A new randomized, prospective trial has shown that orlistat, a commonly prescribed inhibitor of fat absorption, does not help patients with fatty liver disease lose weight, nor does it improve their liver enzymes or insulin resistance.